Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,333
Total Claims
$4.8M
Drug Cost
662
Beneficiaries
$7,244
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+413%
Cost per patient vs peers
$7,244 vs $1,411 avg
+117%
Brand preference vs peers
23.1% vs 10.6% avg
Brand vs Generic
Brand: 5,052 claims · $4.0M
Generic: 16,799 claims · $742K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,003 | $864K |
| Lipase/Protease/Amylase | 303 | $393K |
| Linagliptin | 272 | $370K |
| Diclofenac Epolamine | 621 | $289K |
| Empagliflozin | 169 | $258K |
| Linaclotide | 299 | $251K |
| Dulaglutide | 89 | $187K |
| Dapagliflozin Propanediol | 117 | $185K |
| Dexlansoprazole | 244 | $134K |
| Mirabegron | 133 | $133K |
| Sitagliptin Phos/Metformin Hcl | 94 | $99K |
| Denosumab | 55 | $94K |
| Rivaroxaban | 82 | $92K |
| Sitagliptin Phosphate | 63 | $84K |
| Raloxifene Hcl | 646 | $80K |
Prescribing Profile
Patient Profile
72
Avg Age
58%
Female
1.10
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data